Clinical trials: Esophagogastric Junction Disorder
Malignant Neoplasm of Stomach, Secondary Malignant Neoplasm of Peritoneum
Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis
Patients with histological proven gastric cancer (including cancer of the esophagogastric junction (AEG)) and synchronous peritoneal carcinomatosis, who fulfill the inclusion and exclusion criteria, can be recruited in this…
- Conditions
- Malignant Neoplasm of Stomach, Secondary Malignant Neoplasm of Peritoneum, Secondary Malignant Neoplasm of Other and Unspecified Sites
- Trial name
- GASTRIPEC (NCT02158988)
- Testing
- HIPEC
- Where
- Germany
- Volunteers
- 105 people
- Sponsor
- Charite University, Berlin, Germany
Lymphoma, Advanced Solid Tumors
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101
This is an open label, multicenter, phase 1/1b study to assess safety/tolerability and preliminary clinical activity of E7766 as a single agent administered intratumorally in participants with advanced solid tumors or lymphomas.
- Trial name
- NCT04144140
- Testing
- E7766
- Where
- 13 sites in United States, France and 3 more
- Volunteers
- 24 people
- Sponsor
- Eisai Inc.
Solid Tumors
Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer
This phase I dose escalation study is intended to define the safety, tolerability and maximal tolerable dose (MTD) of MT110 in patients with advanced solid tumors.
- Trial name
- MT110-101 (NCT00635596)
- Testing
- MT110
- Where
- 4 sites in Germany
- Volunteers
- 65 people
- Sponsor
- Amgen Research (Munich) GmbH
Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8
National Cancer Institute "Cancer Moonshot Biobank"
This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study.
- Conditions
- Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT04314401
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 150 sites in United States, Puerto Rico
- Volunteers
- 1,600 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma
Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer
This Phase II study was designed to assess the efficacy and safety of the combination of PD-1 inhibitor, Tucidinostat (chidamide), a histone deacetylase inhibitor, and bevacizumab in advanced Esophageal squamous cell cancer…
- Trial name
- NCT05163483
- Testing
- Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Ruihua Xu
Esophageal Cancer, Gastroesophageal Junction Cancer
STRENGTH Expansion
Patients seen in the EGMDC (Esophageal and Gastric Multidisciplinary Clinic) for treatment planning who are recommended to receive neoadjuvant treatment followed by surgery at UCCC Metro will be offered enrollment into the study.
- Trial name
- NCT04520867
- Testing
- STRENGTH
- Where
- United States
- Sponsor
- University of Colorado, Denver
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, fluorouracil, irinotecan hydrochloride, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT01498289
- Testing
- FOLFOX regimen, docetaxel, fluorouracil
- Where
- 508 sites in United States
- Volunteers
- 213 people
- Sponsor
- SWOG Cancer Research Network
Gastric Cancer, Apatinib
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
The study is to investigate the efficacy and safety of apatinib for the first-fine treatment in elderly patients with locally advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction, unable or unwilling to…
- Conditions
- Gastric Cancer, Apatinib, Biomarker
- Trial name
- NCT03219593
- Testing
- Apatinib mesylate tablets
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Bengbu Medical University
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations
Infigratinib is an oral drug which selectively binds to fibroblast growth factor receptor (FGFR) 1-3. This is a multicenter, open-label, single arm phase IIa study to evaluate the efficacy and safety of Infigratinib in subjects…
- Conditions
- Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor
- Trial name
- FGFR (NCT05019794)
- Testing
- Infigratinib
- Where
- 17 sites in China
- Volunteers
- 80 people
- Sponsor
- LianBio LLC
Solid Tumors, ER/PR Positive Breast Cancer
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
This is a Phase I study to understand the biodistribution of MM-398 and to determine the feasibility of using Ferumoxytol as a tumor imaging agent.
- Conditions
- Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
- Trial name
- NCT01770353
- Testing
- Ferumoxytol, MM-398
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- Ipsen
Gastric Carcinoma
Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma
This study is to evaluate the efficacy and safety of Albumin-bound paclitaxel combined with Toripalimab as first-line/second-line treatment of local advanced or metastatic gastric or gastroesophageal junction carcinoma.
- Trial name
- NCT04443036
- Testing
- Albumin-Bound Paclitaxel, Toripalimab
- Where
- China
- Volunteers
- 44 people
- Sponsor
- China Medical University, China
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Undifferentiated Carcinoma
Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer
This phase II trial studies how well pralatrexate and oxaliplatin work in treating patients with esophageal, stomach, or gastroesophageal junction cancer that cannot be removed by surgery or has spread from the primary site…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Undifferentiated Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma
- Trial name
- NCT01178944
- Testing
- Laboratory Biomarker Analysis, Oxaliplatin, Pralatrexate
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Roswell Park Cancer Institute
OESOPHAGO-GASTRIC CARCINOMA, Oesophageal Adenocarcinoma
AUGMENTED RESPONSE OF VOLATILE BIOMARKERS IN THE ASSESSMENT OF OESOPHAGOGASTRIC CANCER (AROMA2)
Cancer of the stomach and oesophagus is among the world's top five cancers. Survival rates are very poor as the disease presents late and early symptoms are non-specific.
- Conditions
- OESOPHAGO-GASTRIC CARCINOMA, Oesophageal Adenocarcinoma, Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, Oesophageal Cancer Nos
- Trial name
- AROMA2 (NCT07260734)
- Testing
- Breath Test
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Advanced Gastric Cancer, Metastatic Gastric Cancer
Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
This is a multicenter, phase 2, open label study to evaluate safety, tolerability and efficacy of SHR2554 combined with other anti-tumor treatments in patients with advanced or metastatic gastric or gastroesophageal junction…
- Conditions
- Advanced Gastric Cancer, Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT07102901
- Testing
- SHR2554 Tablets, SHR-A1811 Injection, SHR-A1904 Injection
- Where
- 2 sites in China
- Volunteers
- 351 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Gastric (Stomach) Cancer
XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC
This study investigates the efficacy and safety of XELOX chemotherapy combined with sintilimab and hyperbaric oxygen therapy (HBOT) as a first-line treatment for patients with Advanced or Metastatic gastric and gastroesophageal…
- Trial name
- NCT06742411
- Testing
- XELOX+Sintilimab+HBOT
- Where
- 2 sites in China
- Volunteers
- 57 people
- Sponsor
- West China Hospital
Advanced Colorectal Carcinoma, Advanced Digestive System Carcinoma
Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines
This phase I trial investigates the best dose, possible benefits and/or side effects of BAY 1895344 in combination with FOLFIRI in treating patients with stomach or intestinal cancer that that may have spread from where it first…
- Conditions
- Advanced Colorectal Carcinoma, Advanced Digestive System Carcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT04535401
- Testing
- Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing
- Where
- 10 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Bladder Cancer
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
This is a multicenter, open-label, dose-escalation/dose-expansion Phase 1 clinical study to investigate the safety, tolerability, PK profile, pharmacodynamics, and preliminary clinical efficacy of INCB106385 when given as…
- Conditions
- Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT04580485
- Testing
- INCB106385, INCMGA00012
- Where
- 27 sites in United States, Belgium and 4 more
- Volunteers
- 54 people
- Sponsor
- Incyte Corporation
Esophageal Cancer, Stomach Cancer
KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer
This dose-escalation study is to determine the safety, maximum tolerated dose (MTD) and efficacy of KD019 in combination with trastuzumab and mFOLFOX-6.
- Trial name
- NCT02205463
- Testing
- KD019
- Where
- United States
- Sponsor
- NYU Langone Health
ctDNA, Gastric Cancer
Dynamic ctDNA-Guided Adjuvant Therapy in cStage III and IVA Gastric or Gastroesophageal Junction Adenocarcinoma
This is a single-center, prospective, exploratory study evaluating the use of dynamic circulating tumor DNA (ctDNA) monitoring in the postoperative adjuvant treatment setting for patients with stage III or stage IVA gastric or…
- Conditions
- ctDNA, Gastric Cancer, Gastroesophageal Junction (GEJ) Adenocarcinoma, Adjuvant Treatment
- Trial name
- NCT07507916
- Testing
- HLX10, SOX Chemotherapy
- Volunteers
- 32 people
- Sponsor
- Fudan University
Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Spevatamig…
- Conditions
- Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC), Colorectal Cancer
- Trial name
- NCT05482893
- Testing
- Spevatamig (PT886), Paclitaxel, Gemcitabine
- Where
- 11 sites in United States
- Volunteers
- 350 people
- Sponsor
- Phanes Therapeutics